Subacute Sclerosing Panencephalitis (SSPE) - Salient Features

Definition & Etiology

• Causative agent: Measles virus (RNA paramyxovirus)
• Frequency: 1 in 100,000-500,000 measles cases; ~0.1-6 cases per million in unimmunized populations
• Incidence: Dramatically declined with measles vaccination; risk is rising with vaccine hesitancy
• Sex: Males affected 3:1 over females

Pathogenesis (Molecular Basis)

• Defective measles virus maturation in neural cells: aberrant M (matrix) protein and other envelope proteins interfere with assembly and budding of infectious virus particles
• Virus remains in intracellular form and spreads by cell-to-cell contact - hidden from immune surveillance
• There is restricted expression of viral envelope genes - so persistently infected neural cells lack proteins needed to produce infectious particles
• Large numbers of viral nucleocapsid structures accumulate in neurons and glial cells
• Antibody to the M protein is frequently absent (in contrast to antibodies to other measles proteins which are very high)
• Reduced efficiency of measles virus transcription in differentiated brain cells helps maintain the persistent infection

Epidemiology & Risk Factors

• Most patients (85%) are 5-15 years old at diagnosis
• Primary measles infection typically at age <2 years (very early childhood infection is a key risk factor)
• Latent (silent) interval of 6-8 years (range 2-12 years) between acute measles and onset of SSPE
• Early childhood measles (under 2 years) carries a significantly higher risk of SSPE

Clinical Stages (Progressive)

• Course is steadily progressive; death occurs within 1-3 years in most cases
• The progressive ataxic-myoclonic dementia in a child is so characteristic that bedside diagnosis is usually possible

Key Diagnostic Features

EEG (Hallmark)

• Characteristic periodic pattern: bursts of 2-3 Hz high-voltage slow-wave complexes every 5-8 seconds, separated by periods of attenuated ("flat") background activity
• Complexes may last up to 3 seconds, occurring every 4-14 seconds
• This periodicity is essentially pathognomonic

CSF

• Acellular (no pleocytosis) - distinguishes from acute viral encephalitis
• Glucose: normal
• Total protein: normal or mildly elevated
• Markedly elevated gamma globulin (>20% of total CSF protein)
• Oligoclonal IgG bands - representing measles-virus-specific antibody
• CSF antimeasles antibody levels invariably elevated - high intrathecal synthesis (elevated CSF/serum antibody ratio)

Serology

• Very high titers of anti-measles antibody in serum - much higher than after typical measles
• Antibody to M protein is notably absent

MRI

• Often normal early
• With progression: high T2 signal in subcortical white matter and gray matter, initially in posterior hemispheres, spreading to periventricular region and brainstem

Viral Studies

• Measles virus can be cultured from brain tissue using special co-cultivation techniques
• Viral antigen detectable by immunocytochemistry
• Viral genome detectable by in situ hybridization or PCR

Pathology (Histology)

• Eosinophilic nuclear and cytoplasmic inclusion bodies in neurons and glial cells - the histopathological hallmark
• Inclusions contain viral nucleocapsids (confirmed by electron microscopy)
• Lesions involve cerebral cortex and white matter of both hemispheres + brainstem; cerebellum is typically spared
• Destruction of nerve cells (neuronophagia)
• Perivenous cuffing with lymphocytes and mononuclear cells (viral inflammation)
• White matter: degeneration of myelinated fibers (myelin AND axons), perivascular mononuclear cuffing, fibrous gliosis (hence "sclerosing")

Treatment

• No definitive curative therapy
• Isoprinosine (Inosiplex) 100 mg/kg/day orally (max 3 g/day) - may prolong survival and produce some clinical improvement in ~30-35% of patients; never proven in controlled trials
• Intraventricular interferon-alfa (via Ommaya reservoir) combined with oral isoprinosine has been reported to produce improvement or stabilization in ~30-35%
• IV ribavirin + intrathecal interferon-alfa combinations have been tried
• Levetiracetam for symptomatic improvement in myoclonus
• Laboratory endpoint of treatment: eradication of measles antigen from CSF

Prevention

Differential Diagnosis

• Prion disease (Creutzfeldt-Jakob disease) - especially in adults
• Lipid storage diseases (childhood dementias)
• Schilder-type demyelinating disease
• Progressive rubella panencephalitis (similar presentation; caused by persistent rubella virus; CSF shows mild pleocytosis unlike SSPE)

Recent literature note: A 2025 review (PMID 40701692) in Seminars in Pediatric Neurology and a 2026 review (PMID 42156042) confirm the diagnostic and clinical framework above remains current; no new disease-modifying treatments have been established.